have reported that repeated oral administration of the organo-phosphorus compound triphenyl phosphine (TPPn) to the domestic chicken results in neuropathological changes in the spinal cord and peripheral nerves, accompanied by ataxia and paralysis. This study also noted that single doses of TPPn resulted in no inhibition of the enzymes neuropathy target esterase (NTE) and acetylcholinesterase (AChE). We undertook the present study to determine the biochemical, neuropathological, and clinical effects of single doses of TPPn in the European ferret, a mammalian species shown to be susceptible to organophosphorus-induced neurotoxicity. Eight 12-week-old ferrets were each injected subcutaneously with either 250 mg TPPn/kg bw or 500 mg TPPn/kg bw, or with the peanut oil/ethyl ether vehicle. Twenty-four h after dosing, the brains of 5 animals from each dose group were examined for NTE and AChE activities. The remaining 3 animals in each group were observed for 6 days for the development of clinical signs, after which their brains were processed for the presence of axonal degeneration using the Fink-Heimer silver impregnation method. Single injections of TPPn had no effect on the activities of whole-brain NTE or AChE 24 h after injection. The animals observed for clinical signs showed increasing trunk and hindlimb ataxia beginning 4 days after injection, culminating in foreand hindlimb paralysis 6 days after injection. All brains exposed to either dose of TPPn showed widespread axonal degeneration extending from the brainstem and cerebellum into midbrain and forebrain areas. The results of this study support the hypothesis that TPPninduced neurotoxicity is a separate and distinct form of organophosphorus-induced neurotoxicity not dependent on NTE inhibition, and therefore not a variant of organophosphorus-induced delayed neurotoxicity (OPIDN).
A number of different organophosphorus compounds have been tested for their ability to cause organophosphorus-induced delayed neurotoxicity (OPIDN), among them tri-ortho-tolyl phosphate (TOTP), phenyl saligenin phosphate, and diisopropylphosphorofluoridate (DFP). In general, all these compounds share similar effects: an onset of ataxia and paralysis, usually delayed for 14 -21 days, varying amounts of neuropathology involving both peripheral nerves and portions of the central nervous system (CNS), and a 70% threshold inhibition of the enzyme neuropathy target esterase (NTE) (Abou-Donia, 1981 , 1992 Johnson, 1990; Tanaka et al., 1992a) .
We and others have shown that another organophosphorus compound, triphenyl phosphite (TPP), produces clinical signs, neuropathology, and levels of NTE inhibition sufficiently different from those seen with OPIDN-inducing compounds to be classified as a separate and distinct form of organophosphorusinduced neurotoxicity (Lehning et al., 1996; Padilla et al., 1987; Varghese et al., 1995; Veronesi et al., 1986) . With this compound, the time of onset of clinical signs is much sooner than that seen with OPIDN, the neuropathology is far more extensive, involving all levels of the neuraxis, and the 70% inhibition of NTE is not a prerequisite for the observed clinical signs and neuropathology.
Recently, Abou-Donia and his colleagues (1996) reported what they consider to be yet another variant of organophosphorus-induced neurotoxicity in the domestic chicken, caused by exposure to triphenyl phosphine (TPPn). They showed that TPPn, given daily in very large oral doses (500 -5000 mg/kg bw per day for four consecutive days), results in ataxia and paralysis accompanied by axonal degeneration in the spinal cord. In addition, they found that single oral doses of 5000 mg TPPn/kg bw had no effect on activity levels of AChE or NTE 24 h after dosing. This finding is significant, since it is the first report to suggest that both clinical signs and neuropathology indicative of organophosphorus-induced neurotoxicity may occur in the total absence of AChE and NTE inhibition.
As part of our ongoing investigation into the effects of organophosphorus compounds on the central nervous system, we wished to examine the effects of single doses of TPPn on NTE and AChE activities, and the development of clinical signs and neuropathology in the European ferret. In the study conducted by Abou-Donia et al. (1996) , the doses of TPPn administered for the determination of neuropathology and clinical signs were different from those used to assess NTE and AChE activity levels. It is possible that differences in these dosages were responsible for the differences seen in the data and that exposure at identical levels could have led to more consistent positive or negative results. That is, the multiple exposures to TPPn used to evoke the clinical and neuropathological signs might also have resulted in NTE inhibition, while the single, no-observable-effect doses used in the NTE determinations might also not have been enough to yield either clinical or neuropathological sequelae.
The present study was designed to determine whether exposure to single doses of TPPn in the European ferret would result in positive clinical signs and central nervous system (CNR) pathology, while at the same time having no effect on NTE and AChE activity levels. Such a finding would strengthen the suggestion that exposure to triphenyl phosphine results in a specific type of organophosphorus-induced neurotoxicity which is separate and distinct from OPIDN.
MATERIALS AND METHODS
Twenty-four 12-week-old male and female European ferrets (Mustela putorius furo) were used in this study. Based on previous experience, the sex of the animal does not influence the reaction to organophosphorus neurotoxicants such as TOTP, DFP, and TPP. Animals were housed individually during the month of August in outdoor wire mesh cages (72.2 ϫ 61 ϫ 45.7 cm) located at the Michigan State University Experimental Fur Farm. The ferrets were exposed to ambient temperature and humidity, with food and water available ad libitum.
Eight ferrets were each dosed with a single subcutaneous injection of triphenyl phosphine (crystalline, 100% pure, Aldrich Chemical) dissolved in a vehicle of one part ethyl ether and one part peanut oil at 250 mg/kg body weight (bw) (6 males, 2 females) or 500 mg/kg bw (3 males, 5 females). The TPPn did not dissolve in any of the solvents used previously for other organophosphorus compounds, necessitating the use of ethyl ether as the primary solvent. An equal volume of peanut oil was added to facilitate injections. Eight vehicle-control ferrets (4 males, 4 females) were injected subcutaneously with the ethyl ether/peanut oil vehicle at a volume of 2 ml/kg bw.
Twenty-four h after dosing, 5 ferrets from each of the three dose groups were killed by cervical dislocation. The brains were rapidly removed, cut in the mid-sagittal plane, weighed, and frozen on dry ice for subsequent analysis of NTE and AChE activities. NTE activity was determined using the method of Johnson (1977) , and AChE was assayed according to the method of Reed et al. (1966) . Percent inhibition of both NTE and AChE activities was calculated as a function of control activities and analyzed statistically using ANOVA. Statements of significance were based on p Ͻ 0.05.
The remaining 3 ferrets per dose group were observed daily for a total of 6 days in order to determine the time of onset and type of clinical signs and to assess the degree of neuropathy induced by TPPn exposure. The ferrets were removed individually from their cages and placed on a surface providing adequate traction, after which they were observed for a period of approximately 5 min for signs indicative of organophosphorus-induced neurotoxicity. Special attention was paid to the time of onset and degree of severity of trunkor limb-related ataxia and to the onset and severity of flaccid and/or spastic paralysis of the fore-and/or hindlimbs. Overall changes in locomotory patterns were also noted.
Following assessment of clinical signs, all animals in each dose group were deeply anesthetized with sodium pentobarbital (50 mg/kg bw) and perfused transcardially with a 10% formalin-saline solution. Following perfusion, the brains were removed, placed in the fixative for 2 to 3 weeks, transferred to a 30% sucrose-formalin-saline solution for 1 week, frozen with dry ice, and sectioned at a thickness of 40 m in the parasagittal plane. Every 5th section was stained with a variation of the Fink-Heimer silver impregnation method to determine the presence of degenerating axons and axon terminals (Tanaka and Bursian, 1998) . Adjacent sections were stained with cresyl violet to aid in the delineation of nuclear and laminar boundaries. Selected sections were photographed at low power on a Wild M400 Photomacroskop. Nuclei and regions containing degeneration were mapped directly onto the photomicrographs to ensure accurate localization of CNS structures and degeneration. These data were then traced directly onto line drawings. Nuclei and fiber tracts were identified using atlases of the cat brain (Berman, 1968; Berman and Jones, 1982) and reports on the organization of the ferret and mink thalami (Herbert, 1963; Sloane, 1951) . The severity of axonal and terminal degeneration was classified as light, moderate, or heavy.
RESULTS

Injections.
All ferrets tolerated the injections into the dorsum of the neck very well. There were no indications of swelling or obvious damage to the tissues surrounding the injection sites.
Enzyme activities. Effects of TPPn on whole-brain NTE and AChE activities 24 h after dosing are presented in Table 1 . The administration of either 250 mg TPPn/kg bw or 500 mg TPPn/kg bw had no significant effect (p Ͼ 0.05) on wholebrain NTE and AChE activities.
Clinical signs. First apparent at 4 days postdosing in ferrets from both TPPn-dosed groups (Table 2) , clinical signs consisted of ataxic movements of the head and neck along with slight ataxia of the proximal hindlimbs. By 5 days postdosing, the ferrets showed increasingly severe ataxia of the head and neck along with extensor rigidity of the hindlimbs. In addition, movements associated with the proximal forelimbs began to indicate the presence of ataxia. The ataxic forelimbs and extended position of the hindlimbs resulted in a limited ability to locomote, with forward movement achieved through side-toside rolling and undulation of the trunk. On the 6th postdosing day, affected ferrets were unable to hold their heads erect and both the fore-and hindlimbs showed spastic paralysis, with all limbs held in an extended rigid position.
Neuropathology. Silver impregnated axonal and terminal debris was present in the brains of all TPPn-dosed animals. Although there were slight variations in degeneration density from animal to animal, the specific regions containing degenerating axons remained the same and involved nuclei and tracts extending from the medulla through the cerebral hemispheres (Fig. 1) . In each case, degeneration was characterized by the presence of extensive black silver-impregnated debris against a light brown or yellow background, as opposed to the presence of occasional silver-impregnated reticular fibers surrounding blood vessels in areas that had not undergone degeneration. Within nuclear and laminar boundaries, the debris was often scattered and punctate, with no discernible orientation to the degenerating fibers. In areas in which major fiber tracts were undergoing degeneration, the affected axons were oriented in the same direction and could be followed, in many cases, from one level of the brain to another. In most of the brains, the cell bodies were stained a medium brown, so boundaries of specific nuclei or lamina could be defined with some certainty. None of the vehicle control brains showed any signs of terminal degeneration or any changes in cell soma morphology.
In the medulla, the principal nuclei containing moderate to heavy amounts of degeneration included the cochlear nucleus, several vestibular nuclei (medial, lateral, and superior), external cuneate nucleus, superior olivary nuclei, and portions of the pontine gray. Additional light axonal degeneration was present within the gigantocellular tegmental field.
The cerebellum contained varying amounts of degeneration in the white matter and granule cell layers of folia I-XI. No degeneration was noted in the Purkinje cell layer or in the molecular layer of the cortex.
Major midbrain nuclei containing degeneration included the red nucleus and the superior and inferior colliculi. The degeneration within the superior colliculus was densest in the intermediate lamina while degeneration in the inferior colliculus was located within the central nucleus. In the case of the auditory system, degenerating lateral lemniscal fibers were also noted entering the inferior colliculus.
At diencephalic levels, nuclei within both the thalamus and hypothalamus contained degenerating terminals. In the thalamus, the major nuclei containing degeneration included the mediodorsal, ventral posterior, ventral lateral, ventral medial, ventral anterior, lateral geniculate, and medial geniculate nuclei (Figs. 2C, 2D, 3C) . In addition, the medial mammillary nucleus of the hypothalamus contained dense terminal degeneration.
Degeneration within the telencephalon was localized primarily to the cerebral cortex. The sensory cortical areas containing degeneration included the visual, auditory, and somatosensory cortices. In each case terminal degeneration was densest in lamina IV (Figs. 2A, 3A ) with degenerating fibers of passage running through laminae V and VI. The primary motor cortex localized adjacent to and along the banks of the cruciate and coronal sulci on the anterior and posterior sigmoid gyri contained both terminal degeneration (Fig. 2B ) and black silverimpregnated pyramidal cells, with broken fragmented dendrites within lamina V (Fig. 3B) .
Additional telencephalic nuclei containing degenerating axons and terminals included the subthalamic nucleus (Fig. 2D ) and entopeduncular nucleus.
DISCUSSION
The results of the present study indicate that 6 days after a single subcutaneous injection of TPPn, the European ferret shows both severe clinical signs and widespread neuropathology in the central nervous system. In addition, ferrets injected with the same dose of TPPn and examined 24 h after exposure show no detectable inhibition of whole-brain NTE or AChE activities. Taken together, these data support the hypothesis that TPPn should be considered as an entirely separate and distinct organophosphorus compound from those associated with classical OPIDN.
TPPn and NTE and AChE Inhibition
A 2-step process is generally accepted as the initial biochemical event in the development of OPIDN (Johnson, 1982) . The first step is thought to involve phosphorylation of the target nervous system protein, NTE. The second step is conversion of the bound group to a charged form by cleavage of one residual group from the phosphorus in a process called aging. Clinical ataxia in the adult domestic chicken, which has been used as the usual animal model for OPIDN, does not occur without a concomitant high inhibition (Ն70%) and aging of NTE after exposure to the organophosphorus neurotoxicant (Johnson and Glynn, 1995) . In European ferrets administered DFP, clinical signs and neuropathology characteristic of OPIDN were preceded by 86% inhibition of NTE activity as well as 75% inhibition of AChE in the caudal brainstem and cerebellum (Tanaka et al., 1991) . Inhibition of NTE by the related organophosphorus compound triphenyl phosphite (TPP) occurs in all species that have been examined, but there does not seem to be the required threshold inhibition of 70% for manifestation of clinical signs and neuropathology as is the case for OPIDN. For example, Veronesi et al. (1986) and Padilla et al. (1987) reported that doses of TPP that result in clinical signs and neuropathology in the rat cause less than 40% inhibition of brain NTE. In the Japanese quail, Varghese et al. (1995) reported that increasing doses of TPP causes whole-brain NTE activity to be inhibited by 11 to 87% with 40% of the quail showing the lowest NTE inhibition also displaying clinical signs and neuropathology.
The results of the present study confirm those of AbouDonia et al. (1996) in that TPPn does not inhibit brain NTE or AChE when enzyme activity is assessed 24 h after dosing. However, in the latter study, the single oral dose of 5 gm FIG. 1. Line drawings of a series of parasagittal sections through the brain of ferret KF-20 -6D illustrating the location and extent of axonal and terminal degeneration 6 days after a single injection of 250 mg TPPn/kg bw. Section A is closest to the midline, with each subsequent section located approximately 1.6 mm apart. Stippling denotes the location of degenerating axons and axon terminals. Note the widespread degeneration present in all levels of the brain, from the caudal medulla to the cerebral cortex. Abbreviations: AV, anterior ventral thalamic nucleus; Cb, cerebellum; CM, centrum medianum thalamic nucleus; COn, cochlear nuclei; COs, coronal sulcus; CRs, cruciate sulcus; CX, external cuneate nucleus; EN, entopeduncular nucleus; ESs, ectosylvian sulcus; FF, fields of Forel; FTG, gigantocellular tegmental field; ICC, inferior colliculus, central nucleus; LD, lateral dorsal thalamic nucleus; LGN, lateral geniculate nucleus; LL, lateral lemniscus; LP, lateral posterior thalamic nucleus; MAs, marginal sulcus; MD, mediodorsal thalamic nucleus; MGN, medial geniculate thalamic nucleus; MMn, medial mammillary nucleus; PAT, parataenial nucleus; PGL, pontine gray, lateral division; PGM, pontine gray, medial division; PSs, presylvian sulcus; RHs, rhinal sulcus; Rn, red nucleus; SCI, superior colliculus, intermediate lamina; SOL, lateral nucleus of the superior olive; SOM, medial nucleus of the superior olive; SPs, splenial sulcus; SSs, suprasylvian sulcus; SUB, subthalamic nucleus; TGn, tegmental nuclei; VA, ventral anterior thalamic nucleus; VL, ventral lateral thalamic nucleus; VLV, lateral vestibular nucleus, ventral division; VM, ventral medial thalamic nucleus; VMN, medial vestibular nucleus; VPL, ventral posterior lateral thalamic nucleus; VSN, superior vestibular nucleus.
TPPn/kg bw that was administered to chickens to evaluate the effect on brain enzyme activities did not cause clinical signs either. It was only after administration of 4 daily doses of TPPn that clinical signs and neuropathology were evident, but in this case, brain enzyme activities were not measured. In our study, doses of TPPn that caused clinical signs and neuropathology in the European ferret did not affect whole brain NTE and AChE activities 24 h after dosing, thus suggesting that inhibition of NTE is not required for TPPn-induced neurotoxicity, as is true for OPIDN. However, it is possible that inhibition and recovery of enzyme activity took place prior to the 24-h sampling point, or that inhibition of enzyme activity occurred after the 24-h sampling point. We previously reported that maximum inhibition (Ͼ70%) of whole-brain NTE and AChE induced by DFP in the European ferret occurred at 6 h after dosing, and that enzyme activities returned to approximately 50% of control activity by 24 h post-dosing (Tanaka et al., 1991) .
Correlation Between Clinical Signs and Neuropathology
Classical OPIDN has been characterized as having a delayed onset of sensorimotor clinical signs and neuropathology involving the peripheral nerves and long spinal tracts (see AbouDonia, 1981; Abou-Donia and Lapadula, 1990; Baron, 1981) . In the ferret, as well as in other mammalian and non-mammalian species, the clinical signs consist of the gradual onset of ataxia involving the proximal hindlimbs, and progresses over a period of several days to a hindlimb paresis and eventual flaccid paralysis. The underlying neuropathologies accounting for these clinical signs are several. First, it is clear that involve-
FIG. 2.
Plates A and B illustrate axonal and terminal degeneration in the primary visual cortex (A) and primary motor cortex (B), as viewed under darkfield illumination. CNS regions containing silver-impregnated degenerating elements show up as bright areas against a darker background. Plate A shows the dense band of degeneration (arrowheads) located in lamina IV of the primary visual cortex of a ferret 6 days after injection with 500 mg TPPn/kg bw. Plate B shows a similar picture (arrows) in the motor cortex of an animal injected with 250 mg TPPn/kg bw. Plates C and D illustrate axonal and terminal degeneration in the lateral geniculate nucleus (C) and in the mediodorsal (MD) and ventral lateral (VL) thalamic nuclei and the subthalamic nucleus (SUB) (D) of a ferret 6 days after injection with 250 mg TPPn/kg bw. Scale bars, 50 m. ment of the spinocerebellar system and mossy fiber input to the cerebellar cortex is affected by OPIDN compounds. Degeneration of these systems has been shown in the ferret (Tanaka et al., 1991) , cat (Cavanagh and Patangia, 1965) , and chicken (Funk et al., 1994; Pope et al., 1993; Tanaka and Bursian, 1989; Tanaka et al., 1990a) . In addition, involvement of several of the vestibular nuclei has also been reported after exposure to TOTP in the cat (Cavanagh and Patangia, 1965) and to DFP in the ferret (Tanaka et al., 1991) . Degeneration has also been consistently reported in the fasciculus and nucleus gracilis of TOTP and/or DFP-exposed ferrets (Stumpf et al., 1989; Tanaka et al., 1991) and cats (Abou-Donia et al., 1983; Cavanagh and Patangia, 1965) as well as in the more OPIDNresistant rat exposed to TOTP or DFP (Inui et al., 1993; Lehning et al., 1996; Veronesi, 1984) . The degeneration in the spinocerebellar tracts, gracile fasciculus, and vestibular afferents, when combined with degeneration of peripheral nerves and their receptors (Bouldin and Cavanagh, 1979; Cavanagh, 1964; Cavanagh and MacDermot, 1961) , would account for the ataxia seen in these animals. The clinical progression of ataxia into a paresis, followed by a flaccid paralysis, can also be explained by the documented involvement of peripheral nerves (Cavanagh, 1964) .
Other studies have examined the effects of exposure to a related organophosphorus compound, triphenyl phosphite (TPP), and found that the clinical and neuropathological signs associated with TPP are markedly different from those seen after exposure to classical OPIDN compounds (Lehning et al., 1996; Tanaka et al., 1990b Tanaka et al., , 1992b Varghese et al., 1995; Veronesi and Dvergsten, 1987) . With TPP exposure, the onset of clinical signs is much more rapid, occurring within the first 4 to 7 days and rapidly progressing through ataxia to a spastic paralysis. An examination of the CNS shows a much more widespread pattern of degeneration, involving not only the spinal cord, brainstem, and cerebellum, but the midbrain, thalamus, and cerebral cortex as well. While some investigators have classified TPP-induced neurotoxicity as a second form of OPIDN (Abou-Donia, 1992; Abou-Donia and Lapadula, 1990) , others have suggested that the resulting clinical signs and neural damage differ so much from those seen in OPIDN that TPP should not be classified as an OPIDN compound but rather as an entirely separate organophosphorus neurotoxicant (Lehning et al., 1996; Varghese et al., 1995; Veronesi and Dvergsten, 1987) .
An examination of the clinical signs and neuropathology resulting from exposure to TPPn reveals that although they initially are similar to those seen with OPIDN, they are superseded and overshadowed by signs almost identical to those seen following exposure to TPP. Thus, TPPn affects brainstem tracts and cerebellar afferents in ways similar to those affected by the classical OPIDN compounds TOTP and DFP, resulting in initial signs of proximal hindlimb ataxia. This ataxia progresses clinically to a spastic paresis and paralysis, reflecting the further involvement of higher motor regions, including motor thalamic nuclei and the sensorimotor cortex. The particular sequence of clinical signs also suggests that there is a temporal progression in the underlying degeneration pattern such that more rostral midbrain and forebrain areas are involved later than affected regions in the brainstem and cerebellum.
In summary, it appears that the only neurotoxic characteristic that TPPn shares with classic OPIDN compounds is its neuropathic effects on the brainstem and cerebellum with the resultant clinical effects. The absence of any effect on NTE or AChE activity levels, along with its characteristic clinical progression to spastic paralysis caused by an underlying neuropathology involving several forebrain regions, strongly indicate that TPPn should be considered as an organophosphorus compound separate and distinct from those causing OPIDN, but one that is essentially identical to TPP.
